Notice: Availability of Abacavir 120mg, Lamivudine 60mg Dispersible, Scored Tablets For Paediatric Patients

Notice: Availability of Abacavir 120mg, Lamivudine 60mg Dispersible, Scored Tablets For Paediatric Patients

The Paediatric Hospital Level Standard Treatment Guidelines (STGs), the Essential Medicines List (EML) and the South African National Department of Health 2019 Antiretroviral Therapy Clinical Guidelines for the Management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates recommend the use of Abacavir (ABC) and Lamivudine (3TC) as part of the antiretroviral regimens in the weight bands 3-24.9kg (≥ 4 weeks of age to <10 years of age).


Recently, the combination formulation ABC/3TC 120/60mg dispersible, scored tablets have been registered with the South African Health Products Regulatory Authority providing an alternative fixed dose combination treatment for patients on ABC (60 mg) dispersible tablet, ABC (20 mg/ml) oral solution, 3TC (50/5 mg/ml) oral solution, and 3TC (50/5 mg/ml) oral solution. See Table 1 below for dose recommendations according to weight.

Type
Health Circulars
Topic
HIV/AIDS
Language
English
Publisher
National Department of Health
Year
2021